Journal
INDIAN JOURNAL OF DERMATOLOGY
Volume 63, Issue 5, Pages 424-426Publisher
WOLTERS KLUWER MEDKNOW PUBLICATIONS
DOI: 10.4103/ijd.IJD_234_18
Keywords
Breast cancer; cutaneous metastasis; human epidermal growth factor receptor-2; trastuzumab
Categories
Ask authors/readers for more resources
Cutaneous metastasis (CM) from internal malignancies is commonly seen. Sometimes, skin metastases can be the first sign of advanced cancer or an indicator of cancer recurrence. Cases of breast cancer with cutaneous progression after or during trastuzumab therapy have been described in the past, frequently associated with systemic disease progression. However, CM during adjuvant trastuzumab therapy is very rare. It has been hypothesized that cancer cells located in the skin survive and take proliferative advantage by virtue of an immune-tolerance mechanism that hampers trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity. We describe a case of human epidermal growth factor receptor-2-overexpressing breast cancer presenting with diffuse CM during adjuvant trastuzumab therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available